semaglutide vs peptide GLP-1s vs. Peptides: What’s the difference?, GLP-1s, like semaglutide, are designed to reduce appetite and support weight management. However, they don’t directly support metabolism, muscle Peptide Therapy Explained: Benefits, Uses

L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in [PMID: 30530985] Laboratory literature summary: l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in research subjects

The three-phase constipation pattern: acute, adaptation, and resolution Based on patterns across published trials and clinical observation, GLP-1 constipation follows a predictable three-phase trajectory in most patients: Phase 1: Acute onset (weeks 1-4) Constipation begins 7-14 days after starting Ozempic or escalating dose Bowel movement frequency drops from baseline (e.g., daily to every 2-3 days) Stool becomes harder and requires more straining Bloating and abdominal fullness are common Patients often mistake this for "the medication working" because fullness overlaps with satiety Phase 2: Adaptation (weeks 4-12) The colon begins compensating for slowed GLP-1-mediated motility Bowel movement frequency stabilizes (not back to baseline but consistent) Stool consistency improves slightly Symptoms plateau rather than worsen Patients who add fiber or osmotic laxatives during this phase see the most benefit Phase 3: Resolution or persistence (week 12+) 60-70% of patients return to near-baseline bowel habits 15-20% have mild persistent constipation that's manageable with dietary changes 10-15% have moderate to severe persistent constipation requiring ongoing laxative use A small subset (2-3%) cannot tolerate the constipation and discontinue treatment The key clinical decision point is week 12

For semaglutide, the starting dose is typically 0.25 mg/week, increasing gradually to 2.4 mg/week for weight management

Multiplying by 100 converts that volume to the unit markings on your syringe